Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability Study of Ropsacitinib in Healthy Men
NCT04591262Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropsacitinib in plaque psoriasis, sponsored by Pfizer. Primary endpoint: Total radioactivity in urine and feces at Day 14. Started Nov 2020; status: completed.
02
Drugs
ropsacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04591262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591262.